Biodexa Pharmaceuticals Share Price

AIM:BDRXUK£3.5mPharmaceuticals & Biotech

BDRX Share Price Performance

BDRX Community Fair Values

View all narratives

Recent BDRX News & Updates

No updates

Biodexa Pharmaceuticals Plc Key Details

Last Reported Earnings

Jun 30, 2022

Next Reporting Earnings

n/a

Earnings per share (EPS): -0.057
Gross Margin: -621.55%
Net Profit Margin: -832.09%
Debt/Equity Ratio: 0%

View full report ›

Biodexa Pharmaceuticals Plc Competitors

View more competitors

About BDRX

Founded: 2000
Employees: 20
CEO: Stephen Stamp
WebsiteView website: www.biodexapharma.com

Biodexa Pharmaceuticals Plc, a drug delivery technology company, focuses on the bio-delivery and biodistribution of medicines in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTD219, a long-acting formulation of tacrolimus used to lower the risk of organ transplant rejection. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

U.K. Market Performance

7 Days: 0.6%
3 Months: 8.4%
1 Year: 6.9%
Year to Date: 7.1%

The market has been flat over the last week. More promisingly, the market is up 6.9% over the past year. Looking forward, earnings are forecast to grow by 15% annually. Market details ›

🇪🇺 🇬🇧 Momentum Is Returning to European and UK Markets

Richard Bowman

July 2025

The tide is turning for UK & European markets. Index ETFs won’t cut it since sector spreads are massive. Picking the right companies matters now more than ever.

Last Week